Эффективность и безопасность лекарственных средств, применяемых для лечения тошноты и рвоты у беременных женщин


Ушкалова Е.А., Романова О.Л., Илларионова Т.С.

Кафедра общей и клинической фармакологии РУДН, Москва
Обсуждаются различные методы лечения тошноты и рвоты у беременных (нефармакологические и фармакологические). Среди фармакологических широкое распространение, в т.ч. для самолечения, получили средства растительного происхождения (имбирь, перечная мята и листья малины). Лекарственные препараты, используемые для лечения указанных симптомов у беременных, включают пиридоксин, Н1-блокаторы, антагонисты дофаминовых и серотониновых рецепторов, глюкокортикоиды. Однако, несмотря на большой выбор противорвотных средств, доказательные данные об их эффективности и безопасности при применении в качестве антиэметиков у беременных ограниченны. Необходимы дальнейшие исследования эффективности и безопасности лекарственных средств лечения тошноты и рвоты у беременных женщин

Литература


1. King TL, Murphy PA. Evidence-Based Approaches to Managing Nausea and Vomiting in Early Pregnancy J Midwifery Womens Health 2009;54(6):430–44.


2. Magee LA, Mazzotta P, Koren G. Evidencebased view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002;186:256–61.


3. Hollyer T, Boon H, Georgousis A, et al. The use of CAM by women suffering from nausea and vomiting during pregnancy. BMC Complement Altern Med 2002;2:5.


4. Betz O, Kranke P, Geldner G, et al. Is ginger a clinically relevant antiemetic? A systematic review of randomized controlled trials. Forsch Komplementarmed Klass Naturheilkd 2005;12(1):14–23.


5. Matthews A, Dowswell T, Haas DM, et al. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev 2010;9:CD007575.


6. White B. Ginger: An Overview Am Fam Physician 2007;75(11):1689–91.


7. Hoffman T. Ginger: an ancient remedy and modern miracle drug. Hawaii Med J 2007;66(12):326–27.


8. Sahakian V, Rouse D, Sipes S, et al. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: A randomized, double-blind placebo-controlled study. Obstet Gynecol 1991;78:33–6.


9. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: A randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1995;173:881–84.


10. Tan PC, Yow CM, Omar SZ. A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum. Gynecol Obstet Invest 2009; 67(3):151–57.


11. Office of Dietary Supplements, National Institutes of Health Web site. Dietary supplement fact sheet: Vitamin B6. Available from: http://ods. od.nih.gov/factsheets/vitaminb6.asp#h3;


12. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983;309:445–48.


13. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: Meta-analysis. Am J Perinatol 1997;14:119–24.


14. Gilboa SM, Strickland MJ, Olshan AF, et al. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol 2009;85(2):137–50.


15. Kargas GA, Kargas SA, Bruyere HJ Jr, et al. Perinatal mortality due to interaction of diphenhydramine and temazepam. N Engl J Med 1985;313:1417–18.


16. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1976;15:57–64.


17. Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128: 486–88.


18. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15(3):183–92.


19. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36(3):518–44.


20. Bennedsen BE. Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophrenia Research 1998;33:1–26.


21. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case control studies. Psychological Medicine 1996; 26:279–87.


22. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153:592–606.


23. Sobel DE. Fetal damage due to ECT, insulin, coma, chlorpromazine or reserpine. Arch Gen Psychiatry 1960;2:606–11.


24. Levy W, Winniewski K. Chlorpromazine causing extrapyramidal dysfunction in newborn infant of psychotic mother. NY State J Med 1974;74:684–85.


25. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Perinatol 1989; 9:170–72.


26. Ayd F. Is psychiatry in a crisis because of the complications of the psychopharmaceuticals? Dis Nerv Syst 1968;29:23–5.


27. Hauser LA. Pregnancy and psychotropic drugs. Hospital and Community Psychiatry. 1985;36:817–18.


28. Matok I, Gorodischer R, Koren G, et al. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 2009;360:25–8.


29. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62(11):1649–71.


30. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin: Nausea and vomiting of pregnancy. Obstet Gynecol 2004;103:803–14.


31. Van Waes A, Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 1969;9:224–27.


32. Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005;66(3):317–22.


33. Sullivan CA, Johnson CA, Roach H, et al. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 1996;174:1565–68.


34. Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001;7(2):199–213.


35. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapyinduced nausea and vomiting. Cancer Invest 2000;18(2):163–73.


36. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine 3 receptor antagonists. Ann Pharmacother 2003;37(9):1276–86.


Похожие статьи


Бионика Медиа